Constitutively active ALK2 receptor mutants require type II receptor cooperation.

Area of Science:

• Molecular Biology
• Cell Signaling
• Developmental Biology

Background:

• Activating mutations in receptor kinases, like ACVR1 in fibrodysplasia ossificans progressiva (FOP), lead to aberrant signaling and disease.
• The precise mechanism by which constitutively active ALK2 mutants (caALK2) signal, particularly their dependence on type II receptors and ligands, remains unclear.

Purpose of the Study:

• To investigate whether constitutively active ALK2 receptors can signal independently of type II receptors and ligands.
• To define the minimal requirements for caALK2 signaling and its role in heterotopic ossification.

Main Methods:

• Utilized cell-based assays and mouse models with genetic ablation of BMP type II receptors (BmpRII and ActRIIa).
• Assessed signaling, transcription, and heterotopic ossification phenotypes.

Main Results:

• Ablation of BmpRII and ActRIIa abrogated both BMP ligand-mediated and caALK2-mediated signaling and transcription.
• caALK2-induced heterotopic ossification in mice was disrupted upon type II receptor ablation.
• Signaling by GS domain ALK2 mutants could be restored by expressing either BMP type II receptor, independent of ligand binding or kinase activity, but dependent on the cytoplasmic domain.

Conclusions:

• Constitutively active ALK2 mutants signal independently of upstream pathways but require a nonenzymatic scaffolding function from type II receptors.
• Type II receptors are essential for forming functional, potentially ligand-independent signaling complexes with caALK2.
• These findings provide critical insights into the minimal requirements for caALK2 signaling, informing therapeutic strategies for FOP and related conditions.